188 related articles for article (PubMed ID: 30334188)
1. Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease.
Garcia-Miralles M; Yusof NABM; Tan JY; Radulescu CI; Sidik H; Tan LJ; Belinson H; Zach N; Hayden MR; Pouladi MA
Mol Neurobiol; 2019 Jun; 56(6):4464-4478. PubMed ID: 30334188
[TBL] [Abstract][Full Text] [Related]
2. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.
Garcia-Miralles M; Hong X; Tan LJ; Caron NS; Huang Y; To XV; Lin RY; Franciosi S; Papapetropoulos S; Hayardeny L; Hayden MR; Chuang KH; Pouladi MA
Sci Rep; 2016 Aug; 6():31652. PubMed ID: 27528441
[TBL] [Abstract][Full Text] [Related]
3. Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease.
Teo RT; Hong X; Yu-Taeger L; Huang Y; Tan LJ; Xie Y; To XV; Guo L; Rajendran R; Novati A; Calaminus C; Riess O; Hayden MR; Nguyen HP; Chuang KH; Pouladi MA
Hum Mol Genet; 2016 Jul; 25(13):2621-2632. PubMed ID: 27126634
[TBL] [Abstract][Full Text] [Related]
4. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.
Garcia-Miralles M; Geva M; Tan JY; Yusof NABM; Cha Y; Kusko R; Tan LJ; Xu X; Grossman I; Orbach A; Hayden MR; Pouladi MA
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212949
[TBL] [Abstract][Full Text] [Related]
5. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
[TBL] [Abstract][Full Text] [Related]
6. Impaired Remyelination in a Mouse Model of Huntington Disease.
Teo RTY; Ferrari Bardile C; Tay YL; Yusof NABM; Kreidy CA; Tan LJ; Pouladi MA
Mol Neurobiol; 2019 Oct; 56(10):6873-6882. PubMed ID: 30937636
[TBL] [Abstract][Full Text] [Related]
7. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons.
Ehrnhoefer DE; Caron NS; Deng Y; Qiu X; Tsang M; Hayden MR
Exp Neurol; 2016 Sep; 283(Pt A):121-8. PubMed ID: 27296315
[TBL] [Abstract][Full Text] [Related]
8. Varenicline improves motor and cognitive deficits and decreases depressive-like behaviour in late-stage YAC128 mice.
McGregor AL; D'Souza G; Kim D; Tingle MD
Neuropharmacology; 2017 Apr; 116():233-246. PubMed ID: 28025093
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease.
Franciosi S; Ryu JK; Shim Y; Hill A; Connolly C; Hayden MR; McLarnon JG; Leavitt BR
Neurobiol Dis; 2012 Jan; 45(1):438-49. PubMed ID: 21946335
[TBL] [Abstract][Full Text] [Related]
10. Reprint of: Manipulation of microbiota reveals altered callosal myelination and white matter plasticity in a model of Huntington disease.
Radulescu CI; Garcia-Miralles M; Sidik H; Bardile CF; Yusof NABM; Lee HU; Ho EXP; Chu CW; Layton E; Low D; De Sessions PF; Pettersson S; Ginhoux F; Pouladi MA
Neurobiol Dis; 2020 Feb; 135():104744. PubMed ID: 31931139
[TBL] [Abstract][Full Text] [Related]
11. Laquinimod treatment in the R6/2 mouse model.
Ellrichmann G; Blusch A; Fatoba O; Brunner J; Reick C; Hayardeny L; Hayden M; Sehr D; Winklhofer KF; Saft C; Gold R
Sci Rep; 2017 Jul; 7(1):4947. PubMed ID: 28694434
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease.
Ferrari Bardile C; Garcia-Miralles M; Caron NS; Rayan NA; Langley SR; Harmston N; Rondelli AM; Teo RTY; Waltl S; Anderson LM; Bae HG; Jung S; Williams A; Prabhakar S; Petretto E; Hayden MR; Pouladi MA
Proc Natl Acad Sci U S A; 2019 May; 116(19):9622-9627. PubMed ID: 31015293
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease.
Xiang Z; Valenza M; Cui L; Leoni V; Jeong HK; Brilli E; Zhang J; Peng Q; Duan W; Reeves SA; Cattaneo E; Krainc D
J Neurosci; 2011 Jun; 31(26):9544-53. PubMed ID: 21715619
[TBL] [Abstract][Full Text] [Related]
14. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.
Southwell AL; Franciosi S; Villanueva EB; Xie Y; Winter LA; Veeraraghavan J; Jonason A; Felczak B; Zhang W; Kovalik V; Waltl S; Hall G; Pouladi MA; Smith ES; Bowers WJ; Zauderer M; Hayden MR
Neurobiol Dis; 2015 Apr; 76():46-56. PubMed ID: 25662335
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
16. Laquinimod Supports Remyelination in Non-Supportive Environments.
Nyamoya S; Steinle J; Chrzanowski U; Kaye J; Schmitz C; Beyer C; Kipp M
Cells; 2019 Oct; 8(11):. PubMed ID: 31683658
[TBL] [Abstract][Full Text] [Related]
17. Manipulation of microbiota reveals altered callosal myelination and white matter plasticity in a model of Huntington disease.
Radulescu CI; Garcia-Miralles M; Sidik H; Bardile CF; Yusof NABM; Lee HU; Ho EXP; Chu CW; Layton E; Low D; De Sessions PF; Pettersson S; Ginhoux F; Pouladi MA
Neurobiol Dis; 2019 Jul; 127():65-75. PubMed ID: 30802499
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease.
de Paula Nascimento-Castro C; Wink AC; da Fônseca VS; Bianco CD; Winkelmann-Duarte EC; Farina M; Rodrigues ALS; Gil-Mohapel J; de Bem AF; Brocardo PS
Neural Plast; 2018; 2018():4056383. PubMed ID: 30186318
[TBL] [Abstract][Full Text] [Related]
19. Retarded development of neurons and oligodendroglia in rat forebrain produced by hyperphenylalaninemia results in permanent deficits in myelin despite long recovery periods.
Reynolds R; Burri R; Herschkowitz N
Exp Neurol; 1993 Dec; 124(2):357-67. PubMed ID: 7507064
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice.
Brooks S; Higgs G; Janghra N; Jones L; Dunnett SB
Brain Res Bull; 2012 Jun; 88(2-3):113-20. PubMed ID: 20460143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
